Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for Prevention of Bone Loss in Breast Cancer Patients on Letrozole
NCT00171340Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2003
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in osteoporosis (2 arms), sponsored by Novartis. Primary endpoint: Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 months. Started May 2003; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00171340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171340.